The global legal marijuana market size was valued at USD 16.7 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 25.4% from 2023 to 2030. The growing demand for legal marijuana has been a primary factor in the growth of the market. Recently, a large number of countries have legalized the use of medical marijuana for treating various ailments. A number of studies carried out show that medical marijuana and its derivatives can be used to treat symptoms of various diseases, for e.g., it has been successfully used to treat patients with chronic pain, chemotherapy-induced nausea, Parkinson’s, Alzheimer’s, and other neurological diseases. The FDA and other such associations have now started accepting the marijuana derivatives for the prescription of diseases in which it has proven to be useful. This is another factor for the quick turnaround of its legal status in a lot of countries. North America (the U.S. and Canada) has gone a step further and has sanctioned the use of recreational marijuana as well and more than two-thirds of the U.S. states have legalized marijuana.
The pandemic severely affected the logistics network for cannabis and its derivatives and due to the ongoing restrictions, the government authorized dispensaries are also facing shortages owing to disruption in the supply chain network. Import and export of nearly all commodities essential or not have been affected as well. However, with the governments endorsing legalization, the demand has risen and is likely to be high in the next few years. Patients are opting for marijuana derivatives instead of the prescription medicines previously being used.
With the government policies changing, the demand for medical marijuana is also rising. A lot of countries that have legalized the use of medical marijuana are also paving way for its cultivation to cut on the imports and gain revenue in the form of taxes. This, in turn, has generated jobs in the industry and a lot more companies are dabbling in this territory. Several startups in the U.S. and Europe are now focusing on alternate uses of cannabis, other than recreational and medicinal. With so much happening in and around the cannabis industries, the countries are paving way for more liberal policies regarding its cultivation and usage in the medical field as well as industrial use.
Pandemic Impact |
Post COVID Outlook |
The legal marijuana market decreased by 32.4% from 2019 to 2020. |
The market is estimated to witness a y-o-y growth of approximately 25% to 28% in the next 5 years. |
Disruptions in the supply chain, situations of oversupply and undersupply in various geographic locations, and a decrease in prices are the major factors responsible for the revenue decline. |
The shift in the trend of patients toward marijuana for adult use and legalization of marijuana for medical and/or adult-use is anticipated to grow post-pandemic. |
The import-export business has been affected on a large scale owing to lockdowns and changes in regulations with respect to the transportation of marijuana and its products. |
The number of patients adopting cannabis as a treatment is likely to increase due to the growth in the prevalence of medical conditions that require marijuana as a treatment, coupled with the availability of various marijuana-based consumer product types. |
The U.S. is seeing a growing number of cultivators for cannabis, including marijuana since this rakes in more revenues for the government and also cuts down on the cost of import. It has a myriad of applications from medical to industrial and since its legalization, the rise in its sale has been exponential and this has generated new opportunities to increase revenues. With the FDA-level authorizations underway, the market for legal marijuana is only going to expand. A large number of clinical trials will support the prowess of marijuana derivatives for it to be legally prescribed for indications.
In 2022, the oil and tinctures segment held the largest revenue share of over 53.2%. The majority of the countries that have legalized marijuana have done so for its medicinal properties. Marijuana oil and tinctures are being studied extensively for multiple indications in a lot of countries. This is also expected to emerge as the fastest-growing segment over the forecast period in light of recent legalizations for medical cannabis and its derivatives. Oils extracted from cannabis are utilized for the treatment of vomiting and nausea caused due to cancer.
In addition, Oil and tinctures are anticipated to register the fastest growth rate of 26.1%. The cannabinoids that are present in the oil help in improving sleep disorders and alleviate anxiety and stress. The demand for oils and tinctures is anticipated to increase over the forecast period owing to a substantial increase in the number of patients preferring oil as compared to flowers. Moreover, children who need cannabis derivatives for their treatment cannot be suggested to use flowers to smoke and are instead being prescribed oils and tinctures due to the respiratory problems caused by smoking flowers.
The medical segment had the largest revenue share of over 82.6% in 2022. It is expected to grow at a steady rate from 2023 to 2030. The growth in this segment can be attributed to the recent legalization and decriminalization of marijuana for medical use. Patients in these geographic regions have been seen preferring the medical use of marijuana due to the ease of availability and economical pricing.
The chronic pain segment held the largest revenue share of over 25.0% in 2021. Cannabis derivatives have been extensively studied for their potency as an analgesic. It has shown far better results with lesser side effects than the regular medicines being prescribed till now. It has proven to reduce arthritic pain significantly with negligible side effects. With an increase in awareness surrounding the use of medical cannabis and its derivatives, the market is expected to grow steadily over the forecast period.
The adult-use segment is expected to emerge as the fastest-growing segment in the forecast period with the fastest growth rate of 35.3%. In countries like the U.S. and Canada, where adult-use and medical-use cannabis have both been legalized, people are still preferring adult-use marijuana due to the lack of reimbursements available for medical marijuana. In addition, changing consumer behavior toward recreational marijuana is yet another factor anticipated to boost the growth of the segment.
North America held the leading revenue share of over 78.8% in 2022. The rapid increase in the rate at which the government is decriminalizing cannabis for both medical and adult-use or recreational use of marijuana is a key factor driving the regional market. This position is further strengthened by the presence of the majority of the big players in the cannabis market. With more than two-thirds of the U.S. falling under the legal territory for cannabis, the demand and supply both have increased, which is further boosting North America’s position as the forerunner.
Asia is anticipated to register the fastest growth rate of 80.0%. Other regions like Europe, especially the U.K. and South American regions like Mexico, Colombia, and Ecuador have also legalized the use of cannabis, but only in very restricted quantities and for very specific purposes. This market is expected to grow steadily during the coming years in wake of the rising demand in these regions. Several countries are more welcoming to the legalization of cannabis in the Asia Pacific region. With clinical studies as proof of its capability as an analgesic, the countries with a large geriatric population will be fast-tracking the legalization process and can spur the growth of the industry in the region. Several start-ups have emerged for research and production of derivatives of cannabis in the rest of the regions. This is going to further enhance the growth of the cannabis market.
Marijuana products provide various medical benefits to the users, which has increased their adoption for the treatment of various chronic conditions. Hence, they are gaining traction within a short time. Moreover, competition in the global market is high because companies are focused on increasing their product offerings, entering new markets, and gaining new consumers.
The market is expanding at a rapid pace as a large number of European and Asian countries have legalized the medical use of marijuana. The first movers in the market are expected to capitalize by increasing their regional presence and consolidating their market share. Various regulatory, quality and pricing norms are also impacting cross-border trade.
Some prominent players in the global legal marijuana market include:
Canopy Growth Corporation
Aurora Cannabis
Aphria, Inc.
Tilray
ABcann Medicinals, Inc.
The Cronos Group
Maricann Group, Inc.
Organigram Holding, Inc.
Lexaria Corp.
GW Pharmaceuticals
United Cannabis Corporation
Tikun Olam, Ltd.
Report Attribute |
Details |
Market size value in 2023 |
USD 21.0 billion |
Revenue forecast in 2030 |
USD 102.2 billion |
Growth Rate |
CAGR of 25.4% from 2023 to 2030 |
Base year for estimation |
2022 |
Historical data |
2016 - 2021 |
Forecast period |
2023 - 2030 |
Quantitative units |
Revenue in USD million/billion and CAGR from 2023 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Product type, application, region |
Regional scope |
North America; Europe; Asia Pacific, Latin America, Africa |
Country scope |
U.S.; Canada; U.K.; Germany; Italy; Netherlands; Croatia; Poland; Czech Republic; Switzerland; Spain; China; Japan; India; Thailand; New Zealand; Australia; Uruguay; Colombia; Mexico; Brazil |
Key companies profiled |
Canopy Growth Corporation; Aurora Cannabis; Aphria, Inc.; Tilray; ABcann Medicinals, Inc.; The Cronos Group; Maricann Group, Inc.; Organigram Holding, Inc.; Lexaria Corp.; GW Pharmaceuticals; United Cannabis Corporation; Tikun Olam, Ltd. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2016 to 2030. For the purpose of this study, Grand View Research has segmented the global legal marijuana market report based on product type, application, and region:
Product Type Outlook (Revenue, USD Million, 2016 - 2030)
Flower
Oil and Tinctures
Application Outlook (Revenue, USD Million, 2016 - 2030)
Medical
Chronic Pain
Cancer
Depression and Anxiety
Arthritis
Diabetes
Glaucoma
Migraines
Epilepsy
Multiple Sclerosis
AIDS
Amyotrophic Lateral Sclerosis
Alzheimer’s
Post-traumatic Stress Disorder (PTSD)
Parkinson's
Tourette’s
Others
Adult Use
Regional Outlook (Revenue, USD Million, 2016 - 2030)
North America
U.S.
Canada
Europe
U.K.
Germany
Italy
Netherlands
Croatia
Poland
Czech Republic
Switzerland
Spain
Asia Pacific
China
Japan
India
Australia
New Zealand
Thailand
Latin America
Uruguay
Colombia
Mexico
Brazil
Africa
b. The global legal marijuana market size was estimated at USD 16.7 billion in 2022 and is expected to reach USD 21.0 billion in 2023.
b. The global legal marijuana market is expected to grow at a compound annual growth rate of 25.4% from 2023 to 2030 to reach USD 102.2 billion by 2030.
b. The medical-use segment dominated the legal marijuana market with a revenue share of 82.6% in 2022 and is expected to witness significant growth from 2023 to 2030.
b. The oil and tinctures segment dominated the legal marijuana market in 2022 with a revenue share of 53.2%.
b. The chronic pain segment dominated the legal marijuana market in 2021 with a share of 25.7%.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
We value your investment and offer free customization with every report to fulfil your exact research needs.